Synerkine Pharma

Executive Summary

Synerkine Pharma is a Dutch biopharmaceutical company founded in 2019 and based in Leiden, developing a novel class of biologics called Synerkines. These fusion proteins connect different cytokines to enhance immunoregulatory activity, aiming to create non-opioid, disease-modifying therapies for chronic pain conditions. The company leverages its proprietary platform to address the large unmet need in chronic pain management, where current treatments are limited by efficacy and safety concerns, including opioid addiction. By targeting the immune system's role in pain, Synerkine's approach could offer a new paradigm for pain relief without the risks associated with opioids. The company is in the preclinical stage, focusing on lead candidate selection and IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Initiation of IND-enabling studies for lead candidate60% success
• Q2 2026Series A financing round70% success
• H2 2026Presentation of preclinical data at a major pain conference80% success